My Treatment Approach: Metastatic Colorectal Cancer

November 30th 2021

Experts in gastrointestinal cancers review optimal treatment strategies for the management of metastatic colorectal cancer (mCRC).

Optimizing Treatment for Relapsed Refractory Follicular Lymphoma and Marginal Zone Lymphoma

November 22nd 2021

Expert hematologists provide insight on updates on the role of PI3K inhibitors in the treatment of relapsed/refractory MZL and FL.

Targeting FGFR Mutations in Metastatic Urothelial Cancer

November 10th 2021

Drs Arlene O. Siefker-Radtke and Scott T. Tagawa comment on opportunities for treating metastatic urothelial cancer with FGFR targeted therapies based on current trends in molecular testing and emerging therapies.

Major Advances in NSCLC: EGFR Exon 20 Insertion Mutations

October 28th 2021

Practical perspectives on recent data and FDA approvals supporting novel agents that target EGFR exon 20 insertion mutations in non–small cell lung cancer.

Advances in Hormone Receptor Positive Metastatic Breast Cancer

October 27th 2021

Recommendations for managing HR-positive, HER2-negative metastatic breast cancer with CDK4/6 inhibitors and endocrine therapy.

Targetable Gene Rearrangements in Advanced Lung Cancer: Optimized Testing and Management

October 11th 2021

This OncLive Insights features 3 experts who share their thoughts on how the treatment landscape of advanced NSCLC is evolving through use of comprehensive genetic sequencing to identify actionable biomarkers. They summarize how novel therapeutics which target driver alterations in ALK, ROS, RET, or NTRK can be leveraged to personalize and optimize management of advanced NSCLC, ultimately improving survival outcomes.

The New Era of Treating Myelofibrosis

August 30th 2021

Srdan Verstovsek, MD, PhD, and Aaron Gerds, MD, MS, review current treatment strategies and challenges for the management of myelofibrosis and the evolving treatment landscape of the disease.

Treatment-Related Interstitial Lung Disease

August 25th 2021

Through the lens of multidisciplinary management in breast cancer, experts share practical insight on the identification and management of interstitial lung disease.

Neuroendocrine Tumors: Targeted Therapies

August 20th 2021

An overview of neuroendocrine tumors and comprehensive insight on the novel targeted therapies that are improving outcomes for patients.

Management of Myelodysplastic Syndromes in High-Risk Patients

August 5th 2021

Key opinion leaders discuss disease management strategies and novel therapeutics in high-risk patients with myelodysplastic syndromes, focusing on therapeutic options and diagnostic criteria.

Therapeutic Advances for Patients With Chronic Lymphocytic Leukemia

July 30th 2021

This OncLive Insights features 3 experts who elucidate treatment advances for patients with Chronic Lymphocytic Leukemia (CLL). Considering both the frontline and relapsed/refractory setting, these key opinion leaders share their perspectives on optimal risk stratification, molecular targets, and sequencing strategies given data from recent clinical trials.

Acute Lymphoblastic Leukemia: Treatment Strategies and Considerations

July 27th 2021

This OncLive Insights features two oncologists who specialize in the treatment of Acute Lymphoblastic Leukemia (ALL). They discuss risk assessment, approaches to treatment of both Philadelphia chromosome positive (Ph+) and Ph- ALL, the factors they consider when choosing a treatment setting (community or tertiary academic center), use of MRD in ALL, sequencing therapies in the relapsed/refractory setting, and the role of CAR T-cell therapy in this patient population.

Update on Immuno-Oncology Based Therapy for mCRC

July 27th 2021

Considerations for using newer, novel-based combination regimens to treat patients with metastatic colorectal cancer based on strategies explored in recent clinical trials.

The Evolving Treatment Landscape of Metastatic Gastric and Gastroesophageal Junction Cancers

July 12th 2021

Key thought leaders in gastrointestinal oncology build a lively discussion on recent clinical trial updates on immuno-oncology-based combinations for the management of patients with metastatic gastric and gastroesophageal junction cancers and the implications for clinical practice.

Recent Updates in Relapsed or Refractory Multiple Myeloma

June 4th 2021

Key opinion leaders discuss recent updates in treating relapsed or refractory multiple myeloma.

Update on EGFR Antibodies in mCRC

May 25th 2021

Recommendations for appropriately managing metastatic colorectal cancer with anti-EGFR therapy based on recent changes to cetuximab dosing.

Triple-Class Refractory Multiple Myeloma

May 4th 2021

Recommendations for sequencing therapies for triple-class refractory myeloma with options such as selinexor, belantamab mafodotin, or melflufen.

New Targets to Improve Patient Outcomes in MZL and FL

April 20th 2021

Experts in hematology and medical oncology, Anthony Mato, MD, MSCE, and Lori A. Leslie, MD, discuss the current therapeutic options available for marginal zone lymphoma and follicular lymphoma and provide key insights into how the recent accelerated approval of umbralisib has impacted the treatment landscape.

Exploring Immunotherapy Combinations in Endometrial Cancer

April 14th 2021

Experts in gynecologic oncology review key advances in treating advanced endometrial cancer and the promise of combination immunotherapy-based regimens.

Graft Versus Host Disease

April 13th 2021

Corey S. Cutler, MD, MPH, FRCPC; Yi-Bin Chen, MD; and Haris Ali, MD, review currently available treatment options for acute and chronic GVHD and discuss the management of steroid-refractory disease.